Skip to content
DataLookout
Menu

NAGICNCT07225998

Oral N-acetylglucosamine in Crohn's Disease

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Start date pushed from Nov 1, 2026 to Jan 5, 2027 Show 6 more changesShow less
    • Primary endpoints: details revised at 1 of 1 entry
    • Eligibility criteria shortened, about 3 words
    • Secondary endpoints: details revised at 11 of 16 entries
    • Study description expanded, about 9 words
    • Collaborators: details revised at 1 of 2 entries
    • Publications: details revised at 2 of 2 entries
  2. Notable Start date: Jun 30, 2026 to Nov 1, 2026v5
  3. Notable Primary completion pushed from Jun 30, 2027 to Jul 31, 2028
    • Study completion pushed from Oct 31, 2027 to Dec 31, 2028
    • Start date: Jun 1, 2026 to Jun 30, 2026
    v4
  4. Notable Start date: Apr 1, 2026 to Jun 1, 2026v3
  5. Notable Start date: Feb 1, 2026 to Apr 1, 2026v2 Show 5 more changesShow less
    • Eligibility criteria expanded, about 106 words
    • Primary endpoints: 4 to 1
    • Secondary endpoints: 14 to 16
    • Study description expanded, about 96 words
    • Collaborators: 1 to 2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Safety and tolerability: Number of Crohn's disease exacerbations
Timeframe: Weeks 0-6, Weeks 6-9, Weeks 9-15, Weeks 15-18

Secondary (16)

Clinical response as assessed by CDAI score
Clinical response as assessed by mean change in CDAI score
Clinical remission as assessed by CDAI score
Change in serum N-glycome
Change in saliva N-glycome
Show 11 moreShow less
Mean change in serum UDP-GlcNAc
Change in T cell N-glycan branching
Change in T cell activity/responsiveness
Change in fecal mucins
Mean change in fecal calprotectin
Mean change in serum C-Reactive Protein (CRP)
Change in panel-based blood inflammatory cytokines
Change in marker of bile acid homeostasis (FGF19)
Mean change in sCD14
Mean Change in FACIT-Fatigue Patient-reported measure (Fatigue)
Mean Change in Simple Ultrasound Activity (SUS-CD) Score Disease activity measured by intestinal ultrasound

Arms and interventions

Participants with Crohn's disease and carry ZIP8 391-Thr (heterozygous or homozygous carriers)Experimental

N-acetylglucosamine

Participants with Crohn's disease who do not carry ZIP8 391-ThrExperimental

N-acetylglucosamine

Drugs: N-Acetylglucosamine (GlcNAc)

Sites

1 site in 1 country

  • Johns Hopkins University School of MedicineBaltimore, Maryland, United States